<DOC>
	<DOCNO>NCT02893306</DOCNO>
	<brief_summary>The purpose study evaluate whether administration multipotent stromal cell also refer mesenchymal stem cell ( MSCs ) , modify Type 1 Diabetes progression .</brief_summary>
	<brief_title>MSC Administration Management Type 1 Diabetic Patients</brief_title>
	<detailed_description>Aim : evaluate whether single intravenous administration allogeneic bone marrow-derived multipotent stromal cell also refer mesenchymal stem cell ( MSCs ) , modify endogenous insulin secretion capacity exogenous insulin requirement patient Type 1 Diabetes Mellitus . Participants : 10 , female male , 18 year old , diagnose Type 1 Diabetes Mellitus 1 year enrollment , exogenous insulin treatment , pancreatic reserve insulin . Intervention : intravenous administration single dose ( 2-3 millions/Kg ) allogeneic MSCs . Follow : 1 , 6 , 24 month MSC administration .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>differential diagnosis Type 1 Diabetes diagnose perform 1 year enrollment pancreatic reserve insulin high 0.8 nmol/L/h good general health status inform consent patient consent treat physician prove psychiatric competence enrol clinical study pregnancy significant comorbidities HIV , HBV , HCV , HTLV1 , HLTV2 VDRL positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Type1 Diabetes Mellitus</keyword>
	<keyword>Multipotent stromal cell</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Insulin</keyword>
	<keyword>Pancreatic reserve</keyword>
	<keyword>Disease progression</keyword>
</DOC>